Epolia Ramadan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Epolia Ramadan has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Mireille Basselin
National Institutes of Health
9 shared publicationsStanley I. Rapoport
National Institutes of Health
8 shared publicationsMei Chen
National Institutes of Health
7 shared publicationsLisa Chang
Brain Physiology and Metabolism Section, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
5 shared publicationsKaizong Ma
Brain Physiology and Metabolism Section, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
2 shared publicationsAmeer Y. Taha
1 shared publication
Latest Publications
- Retraction
- 25 April 2015
- Published by Springer Nature in Neurochemical Research
- Vol. 40 (5) , 1094
Retraction Note to: Anti-Inflammatory Effects of Chronic Aspirin on Brain Arachidonic Acid Metabolites
- 25 April 2015
- Published by Springer Nature in Neurochemical Research
- Vol. 40 (5) , 1094
RetractionRetraction Note to: Anti-Inflammatory Effects of Chronic Aspirin on Brain Arachidonic Acid Metabolites
- 23 February 2012
- Published by Taylor & Francis in International Journal of Neuroscience
- Vol. 122 (7) , 373-380
Knocking Out the Dopamine Reuptake Transporter (DAT) Does not Change the Baseline Brain Arachidonic Acid Signal in the Mouse
Background. Dopamine transporter (DAT) homozygous knockout (DAT−/−) mice have a 10-fold higher extracellular (DA) concentration in the caudate-putamen and nucleus accumbens than do wildtype (DAT+/+) mice, but show reduced presynaptic DA synthesis and fewer postsynaptic D2 receptors. One aspect of neurotransmission involves DA binding to postsynaptic D2-like receptors coupled to cytosolic phospholipase A2 (cPLA2), which releases the second messenger, arachidonic acid (AA), from synaptic membrane phospholipid. We hypothesized that tonic overactivation of D2-like receptors in DAT−/− mice due to the excess DA would not increase brain AA signaling, because of compensatory downregulation of postsynaptic DA signaling mechanisms. Methods: [1–14C]AA was infused intravenously for 3 min in unanesthetized DAT+/+, heterozygous (DAT+/−), and DAT−/− mice. AA incorporation coefficients k* and rates Jin, markers of AA metabolism and signaling, were imaged in 83 brain regions using quantitative autoradiography; brain cPLA2-IV activity also was measured. Results: Neither k* nor Jin for AA in any brain region, or brain cPLA2-IV activity, differed significantly among DAT−/−, DAT+/–, and DAT+/+ mice. Conclusions: These results differ from reported increases in k* and Jin for AA, and in brain cPLA2 expression, in serotonin reuptake transporter (5-HTT) knockout mice, and suggest that postsynaptic dopaminergic neurotransmission mechanisms involving AA are downregulated despite elevated DA in DAT–/– mice.
- 23 February 2012
- Published by Taylor & Francis in International Journal of Neuroscience
- Vol. 122 (7) , 373-380
Knocking Out the Dopamine Reuptake Transporter (DAT) Does not Change the Baseline Brain Arachidonic Acid Signal in the Mouse
Background. Dopamine transporter (DAT) homozygous knockout (DAT−/−) mice have a 10-fold higher extracellular (DA) concentration in the caudate-putamen and nucleus accumbens than do wildtype (DAT+/+) mice, but show reduced presynaptic DA synthesis and fewer postsynaptic D2 receptors. One aspect of neurotransmission involves DA binding to postsynaptic D2-like receptors coupled to cytosolic phospholipase A2 (cPLA2), which releases the second messenger, arachidonic acid (AA), from synaptic membrane phospholipid. We hypothesized that tonic overactivation of D2-like receptors in DAT−/− mice due to the excess DA would not increase brain AA signaling, because of compensatory downregulation of postsynaptic DA signaling mechanisms. Methods: [1–14C]AA was infused intravenously for 3 min in unanesthetized DAT+/+, heterozygous (DAT+/−), and DAT−/− mice. AA incorporation coefficients k* and rates Jin, markers of AA metabolism and signaling, were imaged in 83 brain regions using quantitative autoradiography; brain cPLA2-IV activity also was measured. Results: Neither k* nor Jin for AA in any brain region, or brain cPLA2-IV activity, differed significantly among DAT−/−, DAT+/–, and DAT+/+ mice. Conclusions: These results differ from reported increases in k* and Jin for AA, and in brain cPLA2 expression, in serotonin reuptake transporter (5-HTT) knockout mice, and suggest that postsynaptic dopaminergic neurotransmission mechanisms involving AA are downregulated despite elevated DA in DAT–/– mice.
- 1 February 2012
- Published by Elsevier in Brain Research Bulletin
- Vol. 87 (2-3) , 154-171
Imaging brain signal transduction and metabolism via arachidonic and docosahexaenoic acid in animals and humans
- 1 February 2012
- Published by Elsevier in Brain Research Bulletin
- Vol. 87 (2-3) , 154-171
Imaging brain signal transduction and metabolism via arachidonic and docosahexaenoic acid in animals and humans
- 1 December 2011
- Published by Elsevier in Neuropharmacology
- Vol. 61 (8) , 1256-1264
Chronic valproate treatment blocks D2-like receptor-mediated brain signaling via arachidonic acid in rats
- 1 December 2011
- Published by Elsevier in Neuropharmacology
- Vol. 61 (8) , 1256-1264
Chronic valproate treatment blocks D2-like receptor-mediated brain signaling via arachidonic acid in rats
- 1 November 2011
- Published by Elsevier in Prostaglandins & Other Lipid Mediators
- Vol. 96 (1-4) , 109-113
Docosahexaenoic acid (DHA) incorporation into the brain from plasma, as an in vivo biomarker of brain DHA metabolism and neurotransmission
- 1 November 2011
- Published by Elsevier in Prostaglandins & Other Lipid Mediators
- Vol. 96 (1-4) , 109-113
Docosahexaenoic acid (DHA) incorporation into the brain from plasma, as an in vivo biomarker of brain DHA metabolism and neurotransmission
- Open Access
- 28 June 2011
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 15 (07) , 931-943
Lamotrigine blocks NMDA receptor-initiated arachidonic acid signalling in rat brain: implications for its efficacy in bipolar disorder
An up-regulated brain arachidonic acid (AA) cascade and a hyperglutamatergic state characterize bipolar disorder (BD). Lamotrigine (LTG), a mood stabi
- 28 June 2011
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 15 (07) , 931-943
Open AccessLamotrigine blocks NMDA receptor-initiated arachidonic acid signalling in rat brain: implications for its efficacy in bipolar disorder
An up-regulated brain arachidonic acid (AA) cascade and a hyperglutamatergic state characterize bipolar disorder (BD). Lamotrigine (LTG), a mood stabi
- Retracted
- 28 October 2010
- Published by Springer Nature in Neurochemical Research
- Vol. 36 (1) , 139-145
RETRACTED ARTICLE: Anti-Inflammatory Effects of Chronic Aspirin on Brain Arachidonic Acid Metabolites
Pro-inflammatory and anti-inflammatory mediators derived from arachidonic acid (AA) modulate peripheral inflammation and its resolution. Aspirin (ASA) is a unique non-steroidal anti-inflammatory drug, which switches AA metabolism from prostaglandin E2 (PGE2) and thromboxane B2 (TXB2) to lipoxin A4 (LXA4) and 15-epi-LXA4. However, it is unknown whether chronic therapeutic doses of ASA are anti-inflammatory in the brain. We hypothesized that ASA would dampen increases in brain concentrations of AA metabolites in a rat model of neuroinflammation, produced by a 6-day intracerebroventricular infusion of bacterial lipopolysaccharide (LPS). In rats infused with LPS (0.5 ng/h) and given ASA-free water to drink, concentrations in high-energy microwaved brain of PGE2, TXB2 and leukotriene B4 (LTB4) were elevated. In rats infused with artificial cerebrospinal fluid, 6 weeks of treatment with a low (10 mg/kg/day) or high (100 mg/kg/day) ASA dose in drinking water decreased brain PGE2, but increased LTB4, LXA4 and 15-epi-LXA4 concentrations. Both doses attenuated the LPS effects on PGE2, and TXB2. The increments in LXA4 and 15-epi-LXA4 caused by high-dose ASA were significantly greater in LPS-infused rats. The ability of ASA to increase anti-inflammatory LXA4 and 15-epi-LXA4 and reduce pro-inflammatory PGE2 and TXB2 suggests considering aspirin further for treating clinical neuroinflammation.
- 28 October 2010
- Published by Springer Nature in Neurochemical Research
- Vol. 36 (1) , 139-145
RetractedRETRACTED ARTICLE: Anti-Inflammatory Effects of Chronic Aspirin on Brain Arachidonic Acid Metabolites
Pro-inflammatory and anti-inflammatory mediators derived from arachidonic acid (AA) modulate peripheral inflammation and its resolution. Aspirin (ASA) is a unique non-steroidal anti-inflammatory drug, which switches AA metabolism from prostaglandin E2 (PGE2) and thromboxane B2 (TXB2) to lipoxin A4 (LXA4) and 15-epi-LXA4. However, it is unknown whether chronic therapeutic doses of ASA are anti-inflammatory in the brain. We hypothesized that ASA would dampen increases in brain concentrations of AA metabolites in a rat model of neuroinflammation, produced by a 6-day intracerebroventricular infusion of bacterial lipopolysaccharide (LPS). In rats infused with LPS (0.5 ng/h) and given ASA-free water to drink, concentrations in high-energy microwaved brain of PGE2, TXB2 and leukotriene B4 (LTB4) were elevated. In rats infused with artificial cerebrospinal fluid, 6 weeks of treatment with a low (10 mg/kg/day) or high (100 mg/kg/day) ASA dose in drinking water decreased brain PGE2, but increased LTB4, LXA4 and 15-epi-LXA4 concentrations. Both doses attenuated the LPS effects on PGE2, and TXB2. The increments in LXA4 and 15-epi-LXA4 caused by high-dose ASA were significantly greater in LPS-infused rats. The ability of ASA to increase anti-inflammatory LXA4 and 15-epi-LXA4 and reduce pro-inflammatory PGE2 and TXB2 suggests considering aspirin further for treating clinical neuroinflammation.
- Open Access
- 1 August 2010
- Published by Elsevier in Journal of Lipid Research
- Vol. 51 (8) , 2334-2340
Extracellular-derived calcium does not initiate in vivo neurotransmission involving docosahexaenoic acid
- 1 August 2010
- Published by Elsevier in Journal of Lipid Research
- Vol. 51 (8) , 2334-2340
Open AccessExtracellular-derived calcium does not initiate in vivo neurotransmission involving docosahexaenoic acid
- RetractedOpen Access
- 28 July 2010
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 31 (2) , 486-493
Imaging Upregulated Brain Arachidonic Acid Metabolism in HIV-1 Transgenic Rats
Human immunodeficiency virus (HIV)-associated infection involves the entry of virus-bearing monocytes into the brain, followed by microglial activation, neuroinflammation, and upregulated arachidonic acid (AA) metabolism. The HIV-1 transgenic (Tg) rat, a noninfectious HIV-1 model, shows neurologic and behavioral abnormalities after 5 months of age. We hypothesized that brain AA metabolism would be elevated in older HIV-1 Tg rats in vivo. Arachidonic acid incorporation from the plasma into the brain of unanesthetized 7-to-9-month-old rats was imaged using quantitative autoradiography, after [1-14C]AA infusion. Brain phospholipase (PLA2) activities and eicosanoid concentrations were measured, and enzymes were localized by immunostaining. AA incorporation coefficients k* and rates Jin, measures of AA metabolism, were significantly higher in 69 of 81 brain regions in HIV-1 Tg than in control rats, as were activities of cytosolic (c)PLA2-IV, secretory (s)PLA2, and calcium independent (i)PLA2-VI, as well as prostaglandin E2 and leukotriene B4 concentrations. Immunostaining of somatosensory cortex showed elevated cPLA2-IV, sPLA2-IIA, and cyclooxygenase-2 in neurons. Brain AA incorporation and other markers of AA metabolism are upregulated in HIV-1 Tg rats, in which neurologic changes and neuroinflammation have been reported. Positron emission tomography with [1-11C]AA could be used to test whether brain AA metabolism is upregulated in HIV-1-infected patients, in relation to cognitive and behavioral disturbances.
- 28 July 2010
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 31 (2) , 486-493
RetractedOpen AccessImaging Upregulated Brain Arachidonic Acid Metabolism in HIV-1 Transgenic Rats
Human immunodeficiency virus (HIV)-associated infection involves the entry of virus-bearing monocytes into the brain, followed by microglial activation, neuroinflammation, and upregulated arachidonic acid (AA) metabolism. The HIV-1 transgenic (Tg) rat, a noninfectious HIV-1 model, shows neurologic and behavioral abnormalities after 5 months of age. We hypothesized that brain AA metabolism would be elevated in older HIV-1 Tg rats in vivo. Arachidonic acid incorporation from the plasma into the brain of unanesthetized 7-to-9-month-old rats was imaged using quantitative autoradiography, after [1-14C]AA infusion. Brain phospholipase (PLA2) activities and eicosanoid concentrations were measured, and enzymes were localized by immunostaining. AA incorporation coefficients k* and rates Jin, measures of AA metabolism, were significantly higher in 69 of 81 brain regions in HIV-1 Tg than in control rats, as were activities of cytosolic (c)PLA2-IV, secretory (s)PLA2, and calcium independent (i)PLA2-VI, as well as prostaglandin E2 and leukotriene B4 concentrations. Immunostaining of somatosensory cortex showed elevated cPLA2-IV, sPLA2-IIA, and cyclooxygenase-2 in neurons. Brain AA incorporation and other markers of AA metabolism are upregulated in HIV-1 Tg rats, in which neurologic changes and neuroinflammation have been reported. Positron emission tomography with [1-11C]AA could be used to test whether brain AA metabolism is upregulated in HIV-1-infected patients, in relation to cognitive and behavioral disturbances.